Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106


In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains.

Jensen JS, Fernandes P, Unemo M.

Antimicrob Agents Chemother. 2014 Jun;58(6):3151-6. doi: 10.1128/AAC.02411-14. Epub 2014 Mar 17.


In vitro activities of the novel bicyclolides modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical Neisseria gonorrhoeae isolates and international reference strains.

Jacobsson S, Golparian D, Phan LT, Ohnishi M, Fredlund H, Or YS, Unemo M.

J Antimicrob Chemother. 2015 Jan;70(1):173-7. doi: 10.1093/jac/dku344. Epub 2014 Sep 1.


In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?

Unemo M, Golparian D, Limnios A, Whiley D, Ohnishi M, Lahra MM, Tapsall JW.

Antimicrob Agents Chemother. 2012 Jul;56(7):3603-9. doi: 10.1128/AAC.00326-12. Epub 2012 Apr 30.


Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae.

Riedel S, Ross JE, Farrell DJ, Flamm RK, Jones RN.

J Clin Microbiol. 2015 Dec;53(12):3888-90. doi: 10.1128/JCM.02250-15. Epub 2015 Sep 16.


Gentamicin Susceptibility among a Sample of Multidrug-Resistant Neisseria gonorrhoeae Isolates in India.

Bala M, Singh V, Bhargava A, Kakran M, Joshi NC, Bhatnagar R.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7518-7521. Print 2016 Dec.


High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.

Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P.

Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80. doi: 10.1128/AAC.05760-11. Epub 2011 Dec 12.


Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea.

Unemo M, Nicholas RA.

Future Microbiol. 2012 Dec;7(12):1401-22. doi: 10.2217/fmb.12.117. Review.


High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against Neisseria gonorrhoeae isolates with various high-level antimicrobial resistance and multidrug resistance.

Jeverica S, Golparian D, Hanzelka B, Fowlie AJ, Matičič M, Unemo M.

J Antimicrob Chemother. 2014 Jul;69(7):1866-72. doi: 10.1093/jac/dku073. Epub 2014 Mar 20.


Emergence and evolution of internationally disseminated cephalosporin-resistant Neisseria gonorrhoeae clones from 1995 to 2005 in Japan.

Shimuta K, Watanabe Y, Nakayama S, Morita-Ishihara T, Kuroki T, Unemo M, Ohnishi M.

BMC Infect Dis. 2015 Sep 17;15:378. doi: 10.1186/s12879-015-1110-x.


A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated Gonorrhea.

Hook EW 3rd, Golden M, Jamieson BD, Dixon PB, Harbison HS, Lowens S, Fernandes P.

Clin Infect Dis. 2015 Oct 1;61(7):1043-8. doi: 10.1093/cid/civ478. Epub 2015 Jun 18.


In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione.

Papp JR, Lawrence K, Sharpe S, Mueller J, Kirkcaldy RD.

Int J Antimicrob Agents. 2016 Sep;48(3):328-30. doi: 10.1016/j.ijantimicag.2016.05.018. Epub 2016 Jul 12.


In vitro activity of solithromycin and its metabolites, CEM-214 and N-acetyl-CEM-101, against 100 clinical Ureaplasma spp. isolates compared with azithromycin.

Furfaro LL, Spiller OB, Keelan JA, Payne MS.

Int J Antimicrob Agents. 2015 Sep;46(3):319-24. doi: 10.1016/j.ijantimicag.2015.04.015. Epub 2015 Jun 19.


High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.

Jacobsson S, Golparian D, Alm RA, Huband M, Mueller J, Jensen JS, Ohnishi M, Unemo M.

Antimicrob Agents Chemother. 2014 Sep;58(9):5585-8. doi: 10.1128/AAC.03090-14. Epub 2014 Jun 30.


Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.

Lo JY, Ho KM, Leung AO, Tiu FS, Tsang GK, Lo AC, Tapsall JW.

Antimicrob Agents Chemother. 2008 Oct;52(10):3564-7. doi: 10.1128/AAC.00198-08. Epub 2008 Jul 28.


Conjunctivitis caused by Neisseria gonorrhoeae isolates with reduced cephalosporin susceptibility and multidrug resistance.

Suzuki T, Kitagawa Y, Maruyama Y, Yamaguchi S, Sakane Y, Miyamoto H, Ohashi Y.

J Clin Microbiol. 2013 Dec;51(12):4246-8. doi: 10.1128/JCM.01946-13. Epub 2013 Sep 11.


Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone.

Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama S, Kitawaki J, Unemo M.

Antimicrob Agents Chemother. 2011 Jul;55(7):3538-45. doi: 10.1128/AAC.00325-11. Epub 2011 May 16.


Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012.

Farrell DJ, Mendes RE, Jones RN.

Antimicrob Agents Chemother. 2015 Apr;59(4):2432-4. doi: 10.1128/AAC.04568-14. Epub 2015 Jan 20.


Enhanced gonococcal antimicrobial surveillance in the era of ceftriaxone resistance: a real-time PCR assay for direct detection of the Neisseria gonorrhoeae H041 strain.

Goire N, Ohnishi M, Limnios AE, Lahra MM, Lambert SB, Nimmo GR, Nissen MD, Sloots TP, Whiley DM.

J Antimicrob Chemother. 2012 Apr;67(4):902-5. doi: 10.1093/jac/dkr549. Epub 2011 Dec 29.


Emergence of decreased susceptibility and resistance to extended-spectrum cephalosporins in Neisseria gonorrhoeae in Korea.

Lee H, Unemo M, Kim HJ, Seo Y, Lee K, Chong Y.

J Antimicrob Chemother. 2015 Sep;70(9):2536-42. doi: 10.1093/jac/dkv146. Epub 2015 Jun 17.

Supplemental Content

Support Center